Vitrolife AB (publ) completes the acquisition of eFertility

Rhea-AI Summary

Vitrolife AB has finalized the acquisition of eFertility, a system and software company specializing in IVF clinic management. eFertility, known for its eWitness and eBase solutions, operates mainly in the Netherlands and is expanding across Europe. In 2023, eFertility achieved revenues of EUR 1.5 million, reflecting the growing demand for IVF witnessing systems. eFertility will be integrated into Vitrolife's Technologies business area, as announced by CEO Bronwyn Brophy O'Connor on May 22, 2024.

Positive

• Completed acquisition of eFertility enhances Vitrolife's portfolio in IVF clinic management.
• eFertility achieved revenues of EUR 1.5 million in 2023, indicating market demand.
• Integration into Technologies business area can drive operational synergies.
• eFertility's advanced systems (eWitness and eBase) add significant technological value.
• eFertility's strong sales pipeline suggests continued growth potential.

Negative

• The acquisition may increase operational costs for Vitrolife in the short term.
• Potential integration challenges could disrupt existing operations temporarily.

GOTHENBURG, Sweden, May 22, 2024 /PRNewswire/ -- Vitrolife AB (publ) has completed the acquisition of eFertility (STB Zorg B.V.) as previously communicated in the press release on 2 May 2024.

eFertility is an innovative system and software company transforming IVF clinic management with its cutting-edge solutions: eWitness (witnessing system to track and trace each step of the IVF procedure) and eBase (a specialised EMR that is compatible with hospital information systems). eFertility has a leading presence in the Netherlands and is rapidly expanding across Europe. In 2023, the company had revenues of EUR 1.5 million with a strong sales pipeline demonstrating the increased demand for witnessing systems in the IVF market. eFertility will be reported under the Technologies business area.  

Gothenburg, May 22, 2024 
VITROLIFE AB (publ)
Bronwyn Brophy O'Connor, CEO

The information was submitted for publication, through the agency of the contact persons set out above, at 22-05-2024 13:30 CET.

Contact: 
Patrik Tolf, CFO, phone +46 (0) 31 766 90 21

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.

This information was brought to you by Cision http://news.cision.com.

https://news.cision.com/vitrolife-ab--publ-/r/vitrolife-ab--publ--completes-the-acquisition-of-efertility,c3986044

The following files are available for download:

https://mb.cision.com/Main/1031/3986044/2814166.pdf

Vitrolife AB (publ) completes the acquisition of eFertility

 

View original content:https://www.prnewswire.com/news-releases/vitrolife-ab-publ-completes-the-acquisition-of-efertility-302152794.html

SOURCE Vitrolife AB (publ)

FAQ

What did Vitrolife acquire on May 22, 2024?

Vitrolife acquired eFertility, an innovative system and software company for IVF clinic management.

What products does eFertility offer?

eFertility offers eWitness, a witnessing system for IVF procedures, and eBase, a specialized EMR compatible with hospital information systems.

What were eFertility's revenues in 2023?

eFertility reported revenues of EUR 1.5 million in 2023.

Where does eFertility primarily operate?

eFertility has a leading presence in the Netherlands and is expanding across Europe.

Which business area will eFertility be reported under?

eFertility will be reported under Vitrolife's Technologies business area.

What is the stock symbol for Vitrolife?

The stock symbol for Vitrolife is VTRLY.